Nobuhiro Yoshijima
A5069746896- Cardiac Valve Diseases and Treatments
- Cardiovascular Function and Risk Factors
- Infective Endocarditis Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Aortic Disease and Treatment Approaches
- Cardiac Imaging and Diagnostics
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Structural Anomalies and Repair
- Pulmonary Hypertension Research and Treatments
- Acute Myocardial Infarction Research
- Cardiac Arrhythmias and Treatments
- Cardiac, Anesthesia and Surgical Outcomes
- Mechanical Circulatory Support Devices
- Coronary Interventions and Diagnostics
Saiseikai Utsunomiya hospital
2022-2024
Keio University
2019-2023
Keio University Hospital
2022
Kajima Corporation (Japan)
2018
To compare safety, efficacy, and hemodynamics of transfemoral transcatheter aortic valve replacement (TAVR) using self-expanding balloon-expandable heart valves (THVs) in patients with a small annulus.Few studies have directly compared TAVR outcomes third-generation THVs, focusing on annuli.In multicenter registry, we analyzed data from 576 annulus who underwent THVs. Propensity score matching was used to adjust baseline clinical characteristics.The device success rate the overall cohort...
Background Subclinical leaflet thrombosis, characterized by hypoattenuated thickening (HALT) on multidetector computed tomography, is common after transcatheter aortic valve replacement (TAVR). Because little known about the long-term natural history of subclinical HALT, we aimed to investigate this in patients who underwent TAVR without using additional anticoagulation. Methods and Results We retrospectively evaluated with Edwards SAPIEN-XT at our institute between October 2013 December...
Background: Current guidelines recommend dual antiplatelet therapy for the first 1 to 6 months after transcatheter aortic valve replacement (TAVR); however, recent studies have reported better outcomes with single than in occurrence of bleeding events, while not increasing thrombotic events. However, no data exist about optimal following TAVR. Methods: Patients who underwent TAVR between October 2013 and May 2017 were enrolled from OCEAN-TAVI Japanese multicenter registry (Optimized...
Objective There is paucity of data on optimal medical treatment, including use beta blockers for patients undergoing transcatheter aortic valve replacement (TAVR). The study aimed to investigate the association and clinical outcomes following TAVR. Methods We examined 2563 who underwent TAVR between October 2013 May 2017 obtained from a prospective multicentre cohort registry, optimised catheter valvular intervention-TAVI registry. compared 2-year cardiovascular non-cardiovascular mortality...
Objective Transcatheter aortic valve replacement (TAVR) improves clinical symptoms in most patients with severe stenosis (AS). However, some do not benefit from the symptom-reducing effects of TAVR. We assessed predictors and outcomes poor symptomatic improvement (SI) after Methods A total 1749 AS undergoing transfemoral TAVR were evaluated using Japanese multicentre registry. Poor SI was defined as readmission for heart failure (HF) within 1 year or New York Heart Association (NYHA) class...
This study investigated the impact and predictive factors of concomitant significant tricuspid regurgitation (TR) evaluated roles right ventricle (RV) function etiology TR in clinical outcomes patients with severe aortic stenosis undergoing transcatheter valve implantation (TAVI).
Background Although transcatheter aortic valve replacement ( TAVR ) is the least invasive treatment for patients with symptomatic stenosis, some hesitate to undergo procedure. We investigated clinical impact of delay after patient refusal . Methods and Results used Japanese OCEAN (Optimized Catheter valvular intervention) regsitry data 1542 who underwent Refusal was defined as at 1 time informed consent. Patients were separated into 2 groups: (28/1542, 1.8%) non-refusal (1514/1542, 98.2%)....
Abstract Objectives This study aimed to compare the clinical impact of mild postprocedural aortic regurgitation (post‐AR) that none‐trivial post‐AR after transcatheter valve implantation (TAVI) and identify vulnerability factors post‐AR. Background Moderate–severe post‐AR, associated with increased mortality, is an important issue. However, remains controversial. Methods results We analyzed data from 1,572 consecutive patients (1,026 546 post‐AR) obtained Optimized transCathEter vAlvular...
Background In patients undergoing transcatheter aortic valve replacement (TAVR), those with small left ventricle (LV) may have an increased risk of poor outcomes, because LV is associated low-flow (LF), ventricular hypertrophy. However, the impact on TAVR remains unknown. Methods and Results We examined 2584 who underwent between October 2013 May 2017 using data from Japanese multicenter registry. On basis American Society Echocardiography guidelines, was defined as end-diastolic dimension...
Abstract Aims Transcatheter aortic valvular replacement (TAVR) is increasingly being performed for elderly patients with stenosis (AS), and current guidelines acknowledge the importance of shared decision‐making in their management. This study aimed to evaluate symptomatic severe AS patients' perspectives on treatment goals identify factors that influence choice. Methods Results We a pre‐procedural cross‐sectional survey using questionnaire at single university hospital. The included three...
Background Ventricular‐arterial coupling predicts outcomes in patients with heart failure. The arterial elastance to end‐systolic ratio (Ea/Ees) is a noninvasively assessed index that reflects ventricular‐arterial coupling. We aimed determine the prognostic value of through Ea/Ees after transcatheter aortic valve replacement predict clinical events. Methods and Results retrieved data on 1378 (70% women) who underwent between October 2013 May 2017 from OCEAN‐TAVI (Optimized transCathEter...